Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ELGX Endologix (ELGX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Endologix Stock (NASDAQ:ELGX) 30 days 90 days 365 days Advanced Chart Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Endologix alerts:Sign Up Key Stats Today's Range$0.07▼$0.0850-Day Range$0.02▼$0.2252-Week Range$0.22▼$7.10Volume85,372 shsAverage Volume1.28 million shsMarket Capitalization$1.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEndologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.Read More… Receive ELGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Endologix and its competitors with MarketBeat's FREE daily newsletter. Email Address ELGX Stock News HeadlinesEndovascular Aneurysm Repair Global Market Report 2022: Advantages Over Open Heart Surgery Driving Adoption & Growth - ResearchAndMarkets.com - Business WireOctober 20, 2022 | businesswire.comVascular Grafts Market to record USD 1.55 Bn incremental growth; Market structure to be fragmented -- Technavio - Yahoo FinanceOctober 19, 2022 | finance.yahoo.comCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.December 23, 2024 | Brownstone Research (Ad)Endovascular Aneurysm Repair Global Market Report 2022: Next Generation Technologies Are Here, Shaping Future Growth Opportunities - Yahoo FinanceOctober 14, 2022 | finance.yahoo.comEndologix Submits Premarket Approval (PMA) Application to FDA for the DETOURTM System. - businesswire.comOctober 10, 2022 | businesswire.comAortic Stent Grafts Market to record USD 781.72 Mn growth -- Driven by rising incidence of aortic aneurysms - PR NewswireSeptember 19, 2022 | prnewswire.comPeripheral Vascular Devices Market Size Worth US$ 16.46 Billion by 2030 at 6.3% CAGR, COVID-19 Impact and Global Analysis by Growth Plus Reports - GlobeNewswireSeptember 19, 2022 | globenewswire.comEndovascular Aneurysm Repair Emerging as Frontrunner with Over Half Revenue Share of Vascular Grafts, Finds Fact.MR - GlobeNewswireAugust 18, 2022 | globenewswire.comSee More Headlines ELGX Stock Analysis - Frequently Asked Questions How were Endologix's earnings last quarter? Endologix, Inc. (NASDAQ:ELGX) released its quarterly earnings data on Monday, May, 11th. The medical instruments supplier reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.13. The medical instruments supplier earned $28.51 million during the quarter, compared to the consensus estimate of $28.50 million. Endologix had a negative net margin of 44.65% and a negative trailing twelve-month return on equity of 63.96%. When did Endologix's stock split? Endologix's stock reverse split on Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Endologix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Endologix investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH) and Gran Tierra Energy (GTE). Company Calendar Last Earnings5/11/2020Today12/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:ELGX CUSIP29266S10 CIK1013606 Webwww.endologix.com Phone949-595-7200FaxN/AEmployees528Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,760,000.00 Net Margins-44.65% Pretax MarginN/A Return on Equity-63.96% Return on Assets-13.26% Debt Debt-to-Equity Ratio0.29 Current Ratio0.39 Quick Ratio0.28 Sales & Book Value Annual Sales$143.37 million Price / Sales0.01 Cash FlowN/A Price / Cash FlowN/A Book Value$3.56 per share Price / Book0.02Miscellaneous Outstanding Shares19,172,000Free FloatN/AMarket Cap$1.41 million OptionableOptionable Beta0.73 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:ELGX) was last updated on 12/23/2024 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Endologix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Endologix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.